Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

Inclusion Criteria

• Inclusion Criteria -- 1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. 2. Age ≥ 18 years at the time of consent. 3. Subjects must meet one of the following criteria: - Subjects suspected or diagnosed with recurrent, locally advanced or metastatic cancer: - Bladder: Urothelial Carcinoma (UC) - Kidney: Clear Cell Renal Cell Carcinoma (ccRCC) - Subjects suspected or diagnosed with recurrent or metastatic cancer: - Colon and Rectum: Microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) Colorectal Cancer (CRC) - Head and Neck: Squamous Cell Carcinoma (HNSCC), excluding nasopharyngeal and salivary gland cancers - Liver: Hepatocellular Carcinoma - Lung: Non-small cell lung cancer (NSCLC) - Skin: Cutaneous Melanoma, excluding Uveal Melanoma - Uterus: endometrial cancer - Subjects suspected or diagnosed with one of the following cancer types eligible for pure ICI neoadjuvant therapy: o Skin: Cutaneous Melanoma, Stage III - Subjects suspected or diagnosed with: - Any solid tumor type that is eligible for pure ICI therapy in the neoadjuvant or advanced/metastatic setting - Any metastatic solid tumor with high TMB, MSI-High or dMMR and are being considered for treatment with ICI therapy. - Any recurrent or metastatic patient with a solid tumor that the clinician plans to treat with ICI therapy. 4. Subjects must be clinically able, at investigator discretion, to undergo a biopsy procedure 5. Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment. Exclusion Criteria -- 1. Subjects who are pregnant 2. Subjects with a known auto-immune disease that would render them ineligible for immune-oncology treatment 3. Immunocompromised subjects, and subjects known to be HIV positive and currently receiving antiretroviral therapy 4. Subjects who are enrolled or plan to be enrolled in a blinded oncology treatment trial